CN114107190A - 一种sma模型小鼠骨髓间充质干细胞的建立方法及应用 - Google Patents
一种sma模型小鼠骨髓间充质干细胞的建立方法及应用 Download PDFInfo
- Publication number
- CN114107190A CN114107190A CN202111467078.0A CN202111467078A CN114107190A CN 114107190 A CN114107190 A CN 114107190A CN 202111467078 A CN202111467078 A CN 202111467078A CN 114107190 A CN114107190 A CN 114107190A
- Authority
- CN
- China
- Prior art keywords
- sma
- mesenchymal stem
- bone marrow
- cells
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 37
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 50
- 238000002474 experimental method Methods 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 239000001963 growth medium Substances 0.000 claims abstract description 11
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 108010019160 Pancreatin Proteins 0.000 claims abstract description 6
- 229940055695 pancreatin Drugs 0.000 claims abstract description 6
- 102100021947 Survival motor neuron protein Human genes 0.000 claims description 60
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 59
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 38
- 238000005406 washing Methods 0.000 claims description 32
- 101150015954 SMN2 gene Proteins 0.000 claims description 14
- 238000011160 research Methods 0.000 claims description 14
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 13
- 238000010166 immunofluorescence Methods 0.000 claims description 13
- 229920002866 paraformaldehyde Polymers 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000002609 medium Substances 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 10
- 239000012895 dilution Substances 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 8
- 238000010791 quenching Methods 0.000 claims description 8
- 230000000171 quenching effect Effects 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000012096 transfection reagent Substances 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 239000012103 Alexa Fluor 488 Substances 0.000 claims description 5
- 108010022222 Integrin beta1 Proteins 0.000 claims description 5
- 102000012355 Integrin beta1 Human genes 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 4
- 238000012937 correction Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 101150075350 FL gene Proteins 0.000 claims description 3
- 238000010240 RT-PCR analysis Methods 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 210000003855 cell nucleus Anatomy 0.000 claims description 2
- 208000022074 proximal spinal muscular atrophy Diseases 0.000 claims 16
- 238000009509 drug development Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102100025304 Integrin beta-1 Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 101150081851 SMN1 gene Proteins 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 102000000132 Alpha tubulin Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101000633246 Dictyostelium discoideum Component of gems protein 1 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000617745 Schizosaccharomyces pombe (strain 972 / ATCC 24843) SMN complex subunit smn1 Proteins 0.000 description 1
- 101150113275 Smn gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70589—CD45
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于生物医疗技术领域,本发明公开了一种SMA模型小鼠骨髓间充质干细胞的建立方法,包括以下步骤:通过对SMA模型小鼠进行基因型鉴定,选取基因型为SMA小鼠BMMSC提取分离,用培养基培养,次日进行换液;倒置显微镜观察细胞形态,待其长满后用胰酶消化,进行传代继续培养;F3代细胞用于后续实验。本发明还公开了SMA模型小鼠骨髓间充质干细胞的构建及鉴定试剂盒,另外还公开了本发明所构建的SMA模型小鼠骨髓间充质干细胞的应用,本发明首次利用原代培养的SMA小鼠骨髓间充质干细胞,原代细胞呈梭形,仅有两个拷贝的SMN2基因,无SMN1基因的干扰,因其来源于SMA小鼠自身,是脊髓性肌萎缩小鼠体外最真实的模拟。
Description
技术领域
本发明属于生物医疗技术领域,具体涉及一种SMA模型小鼠骨髓间充质干细胞的建立方法及应用。
背景技术
脊髓性肌萎缩症(Spinal muscular atrophy,SMA),是一种由于脊髓前角的α运动神经元发生退行性病变,导致运动神经元退化,肌肉萎缩的罕见的常染色体隐性的神经退行性遗传病。目前是婴儿致死率最常见的遗传性神经疾病之一,在新生儿中患病率达1/6000。SMA的致病基因是SMN1基因突变失去功能后,无法产生正常的SMN蛋白,而最终导致疾病发生。在人类中和SMN1同源的SMN2基因外显子7大部分被剪切而仅有少量SMN全长基因,少量SMN有功能蛋白,因此很多研究针对SMN2基因剪接的纠正而增加SMN全长蛋白,来改善SMA症状,如ASO反义寡核苷酸。
关键问题是药物前期的筛选实验需要大量的活体样本进行验证药效,而SMN2基因仅在人类基因组中存在,不可能直接在人身上实验。针对开展大量药物对SMN2验证的方法,目前大体有两种方法,第一、有研究者收集病人来源的细胞进行实验,但是此方法面临伦理问题、收集困难、改造复杂、周期长以及花费高昂等问题。比如将SMA患者的皮肤成纤维细胞或者患者尿液分离的肾小管上皮细胞诱导成IPSC细胞株,进行实验药物筛选。但是该方法诱导产生IPSC的过程繁琐复杂、周期长、而且比较昂贵。或者用人源化的肿瘤细胞,但是这些细胞都有正常功能的SMN1基因,对于研究SMN2的功能有很大的干扰作用也不理想。第二、将SMN2基因导入小鼠,制作成人源化SMN2转基因鼠,直接在SMA疾病小鼠模型上进行试验。但是,构建的SMA转基因小鼠,由于本身SMN基因缺失,仅有2个拷贝的SMN2,产生的SMN蛋白极少,神经系统及外周神经系统功能发生异常,小鼠出生后状态逐渐变差,10天左右就死亡。因此用于药物前期的大量筛选十分也很困难。
SMN2基因功能的纠正对于脊髓性肌肉萎缩症(SMA)病人的重要性:研究表明SMA是由于第五号染色体上运动神经元生存1(survival of motor neuron 1, SMN1)基因发生点突变或缺失导致该基因不能表达有功能的全长SMN蛋白。和动物不同,人类因为染色体5q13区的倒转复制(inverted duplication)产生了一个SMN1的平行同源基因称作SMN2;在外显子7第6位核苷酸由SMN1中的C转变为SMN2中的T(C6T),虽然没有造成翻译中氨基酸的改变,却严重影响了外显子7的列入。SMN2的成熟转录产物中约有90%不包含外显子7,而没有外显子7的蛋白,称作SMN∆7,基本没有功能且极不稳定。SMN2表达的少量全长SMN蛋白虽然不足以补偿SMN1基因的缺陷,却对病人的生存至关重要。
对SMN2功能研究以及治疗药物筛选主要借助人类细胞系,HEK293和hela等细胞系,但这些细胞中SMN1功能正常并没有出现SMA相关表型,因此并不是很好的研究载体,也有研究收集SMA患者身体来源的细胞,并进行IPS诱导改造,但是面临伦理、收集困难、诱导复杂及昂贵等问题,并不广泛;还有就是用的较多的是有SMN2转基因的SMA小鼠,但是小鼠出生只能存活10天左右,给药剂量方式等不易控制,开发成本极高。
目前,骨髓间充质干细胞已广泛用于各种疾病的研究,特别是在一些神经退行性疾病例如帕金森、阿尔兹海默症等疾病上已有相关研究报道。同时,骨髓间充质干细胞在大鼠、小鼠、猪等动物以及人已有报道。关于骨髓间充质干细胞如何利用关于SMN2基因功能以及药物筛选,至今未见有相关研究报道,如果可以顺利培养,那么关于SMN2基因功能和相关药物前期的大量筛选,可以用低成本而且给药多种方式的SMA原代细胞进行,具有很大的研究价值,这正是本发明重点解决的问题。
发明内容
发明目的:针对现有技术中存在问题或不足,本发明提供一种SMA模型小鼠骨髓间充质干细胞的建立方法及应用。
为实现上述发明目的,本发明的实施例提供一种SMA模型小鼠骨髓间充质干细胞的建立方法,其特征在于,包括以下步骤:通过对SMA 模型小鼠进行基因型鉴定,选取基因型为SMA(smn-/-SMN20/2tg)小鼠BMMSC提取分离,用含 10%-20% FBS的DME/F12完全培养基培养,次日进行换液;倒置显微镜观察细胞形态,待其长满(70%-80%)后用 0.25% 胰酶消化,进行传代继续培养;F3代细胞用于后续实验。
进一步的,所述建立方法,还包括细胞鉴定过程:以 1x106个/mL F3代细胞接种于含有小圆玻片的六孔板中,加入 1mL DME/F12完全培养基,混匀,37°C,5% CO2细胞培养箱内过夜培养;次日,从培养箱取出六孔板,弃去完全培养基,用预冷 PBS(1x)洗 3 遍;每孔加入 500μL 4%多聚甲醛溶液,室温 40min,固定;弃去多聚甲醛溶液,用 PBS洗 3次,每次10min;每孔加入 500 μL封闭液,室温 2h;封闭结束后,弃去封闭液,直接敷一抗(integrinbeta-1/CD29;CD44;CD34;CD45;均 1:100稀释),室温孵育 2h,然后 4°C过夜;次日,从 4°C冰箱取出小圆玻片,室温平衡 30min;弃去一抗,PBS洗 3次,每次 10min;避光滴加二抗(Alexa Fluor 488-conjugated Goat anti-rabbit IgG,1:1000稀释),室温孵育 2h;PBS洗 3次,每次 10min;避光条件下,加入抗荧光淬灭液含 DAPI,封片;荧光显微镜拍照保存。
本发明的实施例还提供一种SMA模型小鼠骨髓间充质干细胞建立及鉴定用试剂盒,其特征在于,包括构建用试剂和鉴定用试剂,构建用试剂包括基因型为SMA小鼠的BMMSC、含 10%-20% FBS的DME/F12完全培养基、0.25% 胰酶;鉴定用试剂包括DME/F12完全培养基、 PBS、4%多聚甲醛溶液、封闭液、一抗(integrin beta-1/CD29;CD44;CD34;CD45;均1:100稀释)、二抗(Alexa Fluor 488-conjugated Goat anti-rabbit IgG,1:1000稀释)、抗荧光淬灭液含 DAPI。
优选的,该试剂盒还包括一含有小圆玻片的六孔板。
本发明的实施例另外还提供一种SMA模型小鼠骨髓间充质干细胞在脊髓性肌萎缩药物开发或SMN2基因机制研究方面的应用。
优选的,将所建立的SMA骨髓间充质干细胞通过ASO10-29干预后,显著上调了SMN2FL基因和SMN蛋白,并促进BMMSC细胞增殖。
进一步的,将所建立的SMA模型小鼠骨髓间充质干细胞接种于六孔板中,待SMA模型小鼠BMMSC长至70%-80%,弃去完培,用PBS(1x)洗三遍,弃去PBS,每孔加入2mL完培,设置空白对照组与实验组,空白对照组加入转染试剂,实验组中加入转染试剂+ASO 10-29,37°C,5% CO2培养箱培养48h;进行RT-PCR及Western blot分析,计算SMN2 exon7列入比率;细胞免疫荧光检测SMN蛋白表达情况,研究细胞核内 Gemini bodies数量情况;免疫荧光实验检测SMA BMMSC细胞增殖和细胞凋亡情况。
本发明还公开了一种SMA模型小鼠骨髓间充质干细胞在SMA疾病治疗药物筛选方面的应用。
本发明还公开了一种SMA模型小鼠骨髓间充质干细胞在作为SMN2基因纠正功能研究载体方面的应用。
本发明的上述技术方案的有益效果如下:
(1)本发明首次利用原代培养的SMA小鼠骨髓间充质干细胞(Bone marrowmesenchymal stem cells, BMMSC),具有贴壁生长、可以传代、增殖能力强、分化程度低等优点,原代细胞呈梭形,仅有两个拷贝的SMN2基因,无SMN1基因的干扰,因其来源于SMA小鼠自身,是脊髓性肌萎缩小鼠体外最真实的模拟,本发明的建立方法所获得的SMA模型小鼠骨髓间充质干细胞可用于SMN2机制研究及SMA疾病治疗相关药物开发。本发明所获得SMA小鼠骨髓间充质干细胞可以用于关于SMA疾病治疗药物筛选和SMN2基因纠正功能研究载体。
(2)本发明的实施例验证了通过ASO10-29治疗后,显著上调了SMN2 FL基因和SMN蛋白,并促进BMMSC细胞增殖。因此,本发明建立的SMA BMMSC细胞是体外研究SMN2基因功能或药物筛选的最佳工具细胞。
附图说明
图1为本发明的实施例中 BMMSC细胞培养前期取材过程图。
图2为本发明的实施例中 SMA BMMSC细胞形态及细胞免疫荧光鉴定情况图。图中,骨髓间充质干细胞阳性标志物CD29和CD44表达显著,阴性标志物CD34、CD45基本无表达,符合BMMSC应该有的标志物特异性表达。
图3 为本发明的实施例中ASO治疗SMA BMMSC后SMN2基因和蛋白表达检测结果图。图3A为SMA BMMSC 转染ASO后PCR产物DdeI酶切结果;图3B为SMA BMMSC 转染ASO后SMN蛋白western blot结果;图3C为图3A的定量统计图;图3D为图3B的定量统计图。
图4为本发明的实施例中转染ASO后细胞核内Gemini bodies (gems) 免疫荧光结果图。图中,箭头所示为绿色荧光标记的Nuclear Gemini bodies显著增多。
图5为本发明的实施例中 ASO 治疗后SMA BMMSC细胞增殖情况及凋亡情况图。图5A为EDU 实验,SMA BMMSC 转染ASO后细胞免疫荧光结果;图5B为TUNEL 实验,SMA BMMSC转染ASO后细胞免疫荧光结果;图5C为图5A 的定量统计图;图5D为图5B的定量统计图。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚,下面将结合具体实施例进行详细描述。
实施例一
SMA新生小鼠BMMSC取材方法及细胞培养鉴定
取新生 SMA 模型小鼠(P4)尾尖,进行快速基因型鉴定(Beyotime,D7283M,上海,中国),选取基因型为SMA(smn-/-SMN20/2tg)小鼠BMMSC提取分离,冰上麻醉,于75%乙醇中浸泡,取其四肢,剥离肌肉,取股骨以及肱骨骨髓,用含 10%-20% FBS的DME/F12(Cytiva,Hyclone,USA)完全培养基培养,次日进行换液。倒置显微镜观察细胞形态,待其长满(70%-80%)后用 0.25% 胰酶消化,进行传代继续培养。F3代细胞用于后续实验(图1)。
以 1x106个/mL接种于含有小圆玻片的六孔板中,加入 1mL DME/F12完全培养基,混匀,37°C,5% CO2细胞培养箱内过夜培养。次日,从培养箱取出六孔板,弃去完全培养基,用预冷 PBS(1x)洗 3 遍;每孔加入500μL 4%多聚甲醛溶液,室温 40min,固定;弃去多聚甲醛溶液,用 PBS洗 3次,每次10min;每孔加入 500μL封闭液,室温 2h;封闭结束后,弃去封闭液,直接敷一抗(integrin beta-1/CD29;CD44;CD34;CD45;均 1:100稀释),室温孵育2h,然后 4°C过夜;次日,从 4°C冰箱取出小圆玻片,室温平衡 30min;弃去一抗,PBS洗 3次,每次 10min;避光滴加二抗(Alexa Fluor 488-conjugated Goat anti-rabbit IgG,1:1000稀释),室温孵育 2h;PBS洗 3次,每次 10min;避光条件下,加入抗荧光淬灭液含DAPI,封片;荧光显微镜拍照保存。
本发明所提取分离培养的BMMSC细胞具有贴壁生长、可进行传代及冻存特点,细胞形态呈梭形或扁平型,传至 F3代后细胞形态稳定。对 F3代 BMMSC细胞进行细胞免疫荧光实验,发现BMMSC阳性标志物CD29、CD44分子高表达,而阴性标志物CD34、CD45 分子不表达或低表达。因此,本发明提取分离得到的 SMA 模型 BMMSC 具有骨髓间充质干细胞的特征(图1,2)。
本发明通过对SMA 模型小鼠进行基因型鉴定,选择SMA基因型小鼠进行骨髓间充质干细胞BMMSC提取分离,初步建立SMA疾病动物模型BMMSC培养体系。
其中骨髓间充质干细胞阳性标志物CD29和CD44表达显著,阴性标志物CD34、CD45基本无表达,符合BMMSC应该有的标志物特异性表达。
实施例二
RT-PCR及Western blot分析
SMA BMMSC细胞转染及Total RNA和总蛋白提取
将细胞接种于六孔板中,待SMA模型小鼠BMMSC长至70%-80%,弃去完培,用PBS(1x)洗三遍,弃去PBS,每孔加入2mL完培,设置空白对照组与实验组,空白对照组加入转染试剂(Lipofectamine™ 3000 Reagent,Inviteogen, Thermo Fisher Scientific,USA),实验组中加入转染试剂+ASO 10-29(简称ASO),37°C,5% CO2培养箱培养48h。取转染48h的细胞,弃去完全培养基,用PBS洗3次;每孔加入1mLTrizol(Vazyme,R401-01-AA,南京,中国),收集Total RNA,根据Trizol试剂盒操作说明抽提RNA,离心,用NanoDrop™ 1000Spectrophotometer(Thermo Fisher Scientific,USA)检测细胞RNA浓度。
总RNA的提取及产物酶切电泳
每孔加入120μL蛋白裂解液收集细胞蛋白。取1μg TotalRNA进行逆转录反应,按Reverse Transcriptase试剂盒(Vazyme,南京,中国)说明以总体积10μL建立RT-PCR反应体系,按42°C,45min;85°C,5min;进行RT反应,产物即为cDNA。以此RT产物为模板进行PCR反应,按总体积25μL(12.5μL 2x Taq Master mix,1μL上游引物(HSMNG7-F),1μL下游引物(HSMNG7-R),1μL RT-PCR产物,7μL ddH2O)建立PCR反应体系,95°C,5min;(95°C,30s;60°C,30s;72°C,1min)×35;72°C,7min ;hold 4°C。取少量PCR产物进行1%琼脂糖凝胶电泳,120V,30min;核酸成像系统显影拍照。取剩下的PCR产物加入DdeI限制性内切酶,37°C水浴锅,酶切过夜。第二天,将酶切过夜的产物进行1.5%琼脂糖凝胶电泳,120V,60min;核酸成像系统显影拍照,计算SMN2 exon7列入比率。
Western blot分析
按以下条件进行:80V,30min,调节电压至120V,60min继续进行电泳;300mA,90min进行转膜;5%脱脂奶粉室温封闭2h;敷一抗(β-Actin;Purified Mouse Anti-SMN),4°C过夜;弃一抗,PBST洗3次,每次10min;滴加二抗(HRP标记山羊抗小鼠;HRP标记山羊抗兔;均1:1000稀释),室温2h;弃二抗,PBST洗4次,每次15min;显影仪发光显影。
通过 PCR及酶切反应结果表明:实验组与对照组相比 SMN2 exon7的列入水平显著上升, SMN2 有功能的全长基因显著增多, SMN2 exon7 列入比率由原来的 40%上升至80%(n=3,p<0.05)。通过 western blot实验结果表明:实验组与对照组相比 SMN蛋白表达量显著上调,SMN/β-Actin比值由原来的 1上升至 2(n=3,p<0.05)(图3)。
实施例三
细胞免疫荧光检测SMN蛋白表达情况
将BMMSC细胞接种于含有小圆玻片的12孔板内,转染48h后进行细胞免疫荧光实验。从培养箱取出12孔板,弃去完全培养基,用PBS(1x)洗2-3遍;每孔加入500μL 4%多聚甲醛溶液,室温40min,进行固定;弃去多聚甲醛溶液,用PBS洗3次,每次10min;每孔加入500μL封闭液,室温2h;封闭结束后,弃去封闭液,直接敷一抗(Anti-SMN/Gemin 1,Abcam,ab108531,1:100稀释,U.K;α-TubuLin Antibodyx,Cell Signaling Technology,#3873,1:100,USA),室温2h,然后4℃过夜;第二天,从4℃冰箱取出小圆玻片,复温30min;弃去一抗,PBS洗3次,每次10min;避光滴加二抗(FITC标记的山羊抗小鼠,beyotime,A0568;CY3标记的山羊抗兔,生工生物,D1120062-0100;均1:1000稀释,上海,中国),室温2h;PBS洗3次,每次10min;避光条件下,加入抗荧光淬灭液(含DAPI),封片;使用荧光显微镜拍照。
细胞免疫荧光实验结果表明:实验组与对照组相比细胞核内 Gemini bodies数量显著增多(n=5,p<0.05)(图4)。
实施例四
SMA BMMSC细胞增殖和细胞凋亡检测
转染48h后,弃去培养基,用预冷PBS洗2-3次;按照EDU检测试剂盒(Beyotime,C0071S,上海,中国)说明进行细胞增殖实验。弃PBS,每孔加入500μL已配置好的10μM EDU溶液,37°C孵育2h;弃去培养基,用PBS洗3次,每次5min;每孔加入1mL细胞固定液(PBS配制的含4%多聚甲醛溶液)室温孵育30min;弃固定液,每孔加入1mL 2mg/mL甘氨酸,摇床孵育5min;弃甘氨酸溶液,每孔加入PBS,摇床上洗5min;弃PBS,每孔加入200μL通透液(PBS配制的含0.5% TritonX-100溶液),摇床孵育10min;弃渗透液,PBS洗1次,5min;每孔加入1mL洗涤液(PBS配制的含3% BSA溶液)洗3次,每次5min;每孔加入500μL Click反应液,室温避光孵育30min;弃去反应液,用洗涤液洗3次,每次5min;每孔加入1Ml DAPI,室温避光孵育10min;用洗涤液洗3次,每次10min;用抗荧光淬灭液封片;使用荧光显微镜拍照。
转染48h后,弃去培养基,用预冷PBS洗2-3次,弃PBS,每孔加入500μL 4%多聚甲醛溶液,4°C孵育30min,进行细胞固定;弃去多聚甲醛溶液,用PBS洗3次,每次10min;每孔加入500 μL 0.5% TritonX-100溶液(1xPBS配制),室温孵育10min;弃去0.5% TritonX-100溶液,用PBS洗3次;每孔加入100 μL 1xEquilibration Buffer,室温平衡30min;弃去Equilibration Buffer,避光条件下,每个小圆玻片上加入50 μL TdT缓冲液,37°C孵育1h;弃去TdT缓冲液,用PBS溶液洗4次,每次10min;避光条件下,加入抗荧光淬灭液(含DAPI),封片;使用荧光显微镜拍照。
免疫荧光实验结果表明:实验组与对照组相比 EDU标记的细胞核数量显著增加(n=5,p<0.05),表明 ASO促进SMA模型小鼠BMMSC细胞增殖(图5 A 和图5C)。而实验组与对照组TUNEL标记的细胞核数量没有差异,不具有统计学意义(n=5,p>0.05)。表明ASO不影响SMA模型小鼠BMMSC细胞凋亡(图5 B 和图5D)。
本发明所建立的SMA小鼠骨髓间充质干细胞可通过改变培养基或者血清含量来培养SMA BMMSC,通过SMA小鼠取出的骨髓获得的骨髓间充干细胞培养筛选药物以及SMN2基因机制研究均属于本专利保护范围。
以上所述是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明所述原理的前提下,还可以作出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种SMA模型小鼠骨髓间充质干细胞的建立方法,其特征在于,包括以下步骤:通过对SMA 模型小鼠进行基因型鉴定,选取基因型为SMA(smn-/-SMN20/2tg)小鼠BMMSC提取分离,用培养基培养,次日进行换液;倒置显微镜观察细胞形态,待其长满(70%-80%)后用 0.25%胰酶消化,进行传代继续培养;F3代细胞用于后续鉴定。
2.根据权利要求1所述的一种SMA模型小鼠骨髓间充质干细胞的建立方法,其特征在于,所述培养基为含 10%-20% FBS的DME/F12完全培养基。
3.根据权利要求1所述的一种SMA模型小鼠骨髓间充质干细胞的建立方法,其特征在于,还包括细胞鉴定过程:以 1x106个/mL F3代细胞接种于含有小圆玻片的六孔板中,加入1mL DME/F12完全培养基,混匀,37°C,5% CO2细胞培养箱内过夜培养;次日,从培养箱取出六孔板,弃去完全培养基,用预冷 PBS(1x)洗 3 遍;每孔加入 500μL 4%多聚甲醛溶液,室温 40min,固定;弃去多聚甲醛溶液,用 PBS洗 3次,每次10min;每孔加入 500 μL封闭液,室温 2h;封闭结束后,弃去封闭液,直接敷一抗(integrin beta-1/CD29;CD44;CD34;CD45;均为 1:100稀释),室温孵育 2h,然后 4°C过夜;次日,从 4°C冰箱取出小圆玻片,室温平衡30min;弃去一抗,PBS洗 3次,每次 10min;避光滴加二抗(Alexa Fluor 488-conjugatedGoat anti-rabbit IgG,1:1000稀释),室温孵育 2h;PBS洗 3次,每次 10min;避光条件下,加入抗荧光淬灭液含 DAPI,封片;荧光显微镜拍照保存。
4.一种根据权利要求2所述的SMA模型小鼠骨髓间充质干细胞建立及鉴定用试剂盒,其特征在于,包括构建用试剂和鉴定用试剂,构建用试剂包括基因型为SMA小鼠的BMMSC、含10%-20% FBS的DME/F12完全培养基、0.25% 胰酶;鉴定用试剂包括DME/F12完全培养基、PBS、4%多聚甲醛溶液、封闭液、一抗(integrin beta-1/CD29;CD44;CD34;CD45;均 1:100稀释)、二抗(Alexa Fluor 488-conjugated Goat anti-rabbit IgG,1:1000稀释)、抗荧光淬灭液含 DAPI。
5.根据权利要求2所述的一种SMA模型小鼠骨髓间充质干细胞建立及鉴定用试剂盒,其特征在于,该试剂盒还包括一含有小圆玻片的六孔板。
6.一种权利要求1所述建立的SMA模型小鼠骨髓间充质干细胞在脊髓性肌萎缩药物开发或SMN2基因机制研究方面的应用。
7.根据权利要求6所述的应用,其特征在于,将所建立的SMA骨髓间充质干细胞通过ASO10-29干预后,能够显著上调了SMN2 FL基因和SMN蛋白,并促进BMMSC细胞增殖。
8.根据权利要求7所述的应用,其特征在于,将所建立的SMA骨髓间充质干细胞接种于六孔板中,待SMA模型小鼠BMMSC长至70%-80%,设置空白对照组与实验组,空白对照组加入转染试剂,实验组中加入转染试剂+ASO 10-29;对实验组和空白对照组,进行RT-PCR及Western blot分析,计算SMN2 exon7列入比率及检测SMN蛋白表达量;进行细胞免疫荧光检测SMN蛋白表达情况,研究细胞核内 Gemini bodies数量情况;进行免疫荧光实验检测SMABMMSC细胞增殖和细胞凋亡情况。
9.一种权利要求1所述建立的SMA模型小鼠骨髓间充质干细胞在SMA疾病治疗药物筛选方面的应用。
10.一种权利要求1所述建立的SMA模型小鼠骨髓间充质干细胞在作为SMN2基因纠正功能研究载体方面的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111467078.0A CN114107190A (zh) | 2021-12-02 | 2021-12-02 | 一种sma模型小鼠骨髓间充质干细胞的建立方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111467078.0A CN114107190A (zh) | 2021-12-02 | 2021-12-02 | 一种sma模型小鼠骨髓间充质干细胞的建立方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114107190A true CN114107190A (zh) | 2022-03-01 |
Family
ID=80366153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111467078.0A Pending CN114107190A (zh) | 2021-12-02 | 2021-12-02 | 一种sma模型小鼠骨髓间充质干细胞的建立方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114107190A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117363660A (zh) * | 2023-09-16 | 2024-01-09 | 赛业(苏州)生物科技有限公司 | 一种构建sma小鼠模型的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103911346A (zh) * | 2014-03-27 | 2014-07-09 | 江苏雄鸣医药科技有限公司 | 一种脊髓性肌萎缩症smn基因的敲除方法及细胞模型 |
US20190136192A1 (en) * | 2017-11-09 | 2019-05-09 | Cell Medicine, Inc. | Mesenchymal stem cell therapy for spinal muscular atrophy |
CN112481272A (zh) * | 2020-12-23 | 2021-03-12 | 南通大学 | Nova1促smn2外显子7列入的验证方法及其应用 |
-
2021
- 2021-12-02 CN CN202111467078.0A patent/CN114107190A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103911346A (zh) * | 2014-03-27 | 2014-07-09 | 江苏雄鸣医药科技有限公司 | 一种脊髓性肌萎缩症smn基因的敲除方法及细胞模型 |
US20190136192A1 (en) * | 2017-11-09 | 2019-05-09 | Cell Medicine, Inc. | Mesenchymal stem cell therapy for spinal muscular atrophy |
CN112481272A (zh) * | 2020-12-23 | 2021-03-12 | 南通大学 | Nova1促smn2外显子7列入的验证方法及其应用 |
Non-Patent Citations (3)
Title |
---|
CHIA-YEN WU等: "Proteomic assessment of a cell model of spinal muscular atrophy", 《BMC NEUROSCI 》, vol. 12, no. 25, pages 2 * |
LI-KAI TSAI等: "Therapy development for spinal muscular atrophy in SMN independent targets", 《NEURAL PLAST 》, vol. 2012, pages 1 - 13 * |
罗新明等: "丙戊酸对脊髓性肌萎缩症患者神经元样细胞 SMN2基因mRNA表达的影响", 《中华神经科杂志》, vol. 39, no. 3, pages 2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117363660A (zh) * | 2023-09-16 | 2024-01-09 | 赛业(苏州)生物科技有限公司 | 一种构建sma小鼠模型的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109628404B (zh) | 猪皮下脂肪前体细胞永生化细胞系的构建方法及用途 | |
Zhang et al. | Longitudinal epitranscriptome profiling reveals the crucial role of N6-methyladenosine methylation in porcine prenatal skeletal muscle development | |
CN111154763B (zh) | 长链非编码RNA lncMGPF在调控猪肌肉发育功能中的应用 | |
CN108504625A (zh) | 一种小鼠成纤维细胞及其用途 | |
Haynes et al. | Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures | |
CN104726500A (zh) | MicroRNA26b-3p抑制剂在制备人脐带来源间充质干细胞中的应用 | |
Chen et al. | Isolation and culture of mouse alveolar type II cells to study type II to type I cell differentiation | |
CN111454990B (zh) | 人颈静脉球副神经节瘤永生化细胞株及其应用 | |
CN102618500A (zh) | 一种体外诱导人间充质干细胞分化为胰岛素分泌细胞的方法 | |
CN114107190A (zh) | 一种sma模型小鼠骨髓间充质干细胞的建立方法及应用 | |
CN101705227B (zh) | 抑制人AP-2alpha基因表达的siRNA在抗宫颈癌药物制备中的应用 | |
CN113046322B (zh) | 一种永生化的奶牛胎盘滋养层细胞系及其构建方法 | |
Zhang et al. | The therapeutic effects of tyrosine hydroxylase gene transfected hematopoetic stem cells in a rat model of Parkinson’s disease | |
CN113502269B (zh) | 一种通过干扰uba2表达抑制牛骨骼肌卫星细胞增殖和成肌分化的方法 | |
Kittipassorn et al. | Characterization of the novel spontaneously immortalized rat Müller cell line SIRMu-1 | |
CN114563330A (zh) | 一种自身蛋白与间充质干细胞Th1免疫调节相关性的评估方法 | |
Ulaangerel et al. | Condition optimization for electroporation transfection in horse skeletal muscle satellite cells | |
Ghori et al. | Induced pluripotent stem cells from urine of Duchenne muscular dystrophy patients | |
EP3943609A1 (en) | Molecular marker detection and regulating methods in de-servitization state of cells | |
CN107338243B (zh) | 重组间充质干细胞及其制备方法 | |
CN114591915B (zh) | 一种大黄鱼体外诱导多能性干细胞的方法 | |
CN115976111A (zh) | 一种通过干扰hnrnpab表达促进牛骨骼肌卫星细胞成肌分化的方法和应用 | |
Li et al. | Adult rat hippocampus soluble factors: A novel transplantation model mimicking intracranial microenvironment for tracing the induction and differentiation of adipose-derived stromal cells in vitro | |
CN117070469A (zh) | 含有nlrp7突变的家族性复发性葡萄胎患者特异性诱导多能干细胞系及构建方法 | |
CN115074363A (zh) | 环状RNA circCLTH在促进骨骼肌细胞增殖或分化中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |